Reuters logo
BRIEF-Actinogen Medical received feedback from FDA
September 29, 2016 / 11:42 AM / a year ago

BRIEF-Actinogen Medical received feedback from FDA

Sept 29 (Reuters) - Actinogen Medical Ltd

* Will communicate with FDA and if questions cannot be resolved in time, will not be able to recruit patients in phase ii trial by end of 2016

* Received feedback from FDA with further questions around potential safety surveillance of drug xanamem Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below